Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Tables)

v2.4.0.6
Commitments and Contingencies (Tables)
 3 Months Ended
Mar. 31, 2013
Abbott Biotherapeutics Corp [Member]
  
Milestone Payments Milestone Method [Line Items]  
Summary of milestone payment
Milestones
  
Payments
  
       
(1) when Company initiates a Phase I Clinical Trial of a licensed product
  
$
750,000
  
(2) when Company initiates a Phase II Clinical Trial of a licensed product
    
750,000
  
(3) when Company initiates a Phase III Clinical Trial of a licensed product
    
1,500,000
  
(4) Biological License Application filing with U.S. FDA
    
1,750,000
  
(5) First commercial sale
    
1,500,000
  
(6) after the first $10,000,000 in net sales
    
1,500,000
  
MSKCC [Member]
  
Milestone Payments Milestone Method [Line Items]  
Summary of milestone payment
Milestones
  
Payments
  
       
1) filing of an New Drug Application (“NDA”) or regulatory approval
      
for each licensed product
  
$
750,000
  
(2) upon the receipt of regulatory approval from the U.S. FDA for each
        
licensed product
    
1,750,000